Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.

摘要: Background. An index is needed to assess the status of patients with rheumatoid arthritis (RA), as none existing measures are applicable all individual patients. The 28-joint Disease Activity Score (DAS28) most specific and widely used index. Routine Assessment Patient Index Data (RAPID3) an containing only 3 patient self-report core dataset measures, without a laboratory test or formal joint count, simple scoring. RAPID3 correlated significantly DAS28, but calculated in 5–10 seconds on Multidimensional Health Questionnaire (MDHAQ), compared 114 for DAS28. Methods. DAS28 (0–10 scale) categories high, moderate, low activity, remission (≤ 2.6, 2.6–3.2, 3.21–5.1, > 5.1, respectively) proposed (0–30 severity (0 ≤ 3, 3.1–6, 6.1–12, 12) were taking abatacept control-treated at endpoint Abatacept Inadequate Response Methotrexate (AIM) Trial Treatment Anti-TNF INadequate Responders (ATTAIN) clinical trials, using cross-tabulations kappa statistics. Results. Overall, 92%–99% classified having high activity had moderate severity, while 64%–83% remission; 50%–82% good poor EULAR responses responses. Kappa values ranged from 0.25 0.48, weighted kappas 0.32 0.52, indicating fair agreement 2 indices. Conclusion. Proposed response yield comparable results criteria AIM ATTAIN. more trials. does not preclude also scoring may be informative infrastructure routine care.